<DOC>
	<DOC>NCT02406014</DOC>
	<brief_summary>This is a phase 4, multi-centre, randomized, two group, open label, active controlled, parallel group, 17 week trial.</brief_summary>
	<brief_title>Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp</brief_title>
	<detailed_description>All subjects who qualify for this trial are to have 4 to 8 clinically typical, visible and discrete AK lesions within a contiguous 25 cm2 treatment area on the face or scalp. Eligible subjects will be randomised in a 1:1 ratio to the following treatment groups: - Treatment Group A: Ingenol mebutate gel 0.015%, once daily for 3 consecutive days for the first treatment course. At 8 weeks after treatment initiation, subjects who present with existing AKs or newly emergent AKs in the treatment area will receive one more treatment course of ingenol mebutate gel 0.015%, daily for 3 consecutive days. - Treatment Group B: Diclofenac sodium gel 3%, (0.5 grams), twice daily for 90 days.</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis, Actinic</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>1. Following verbal and written information about the trial, subject must provide informed consent documented by signing the Informed Consent Form (ICF) prior to any trial related procedures 2. Subjects with 4 to 8 clinically typical, visible and discrete AKs within a contiguous 25 cmÂ² treatment area on the face or scalp 1. Location of the selected treatment area: on the periorbital skin on the perioral skin/around the nostrils within 5 cm of an incompletely healed wound within 10 cm of a suspected BCC or SCC or other neoplasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>